G PROTEIN-COUPLED RECEPTORS (GPCRs, also designated as heptahelical receptors or 7TMRs) are integral membrane proteins characterized by seven transmembrane ␣-helices. GPCRs, with ϳ800 genes, represent the largest transmembrane receptor superfamily in the human genome (11) . Many intercellular messengers, including hormones, neurotransmitters, chemokines, growth and developmental factors, bioactive lipids, proteases, amino acids, nucleotides, biogenic amines and ions, initiate their characteristic effects on their target cells by binding to ϳ350 nonchemosensory GPCRs and thereby function as neurotransmitters, local regulators, or systemic hormones. Accordingly, GPCRs mediate the majority (ϳ80%) of signal transduction across cell membranes in the organism (7) . GPCRs and their cognate agonists are not only implicated in the regulation of postmitotic functions of differentiated cells but also act as growth factors and are implicated in autocrine/ paracrine stimulation of proliferation of cancer cells (16) . At present, GPCRs are the most prominent targets for therapeutic drugs as they play an important role in a variety of diseases from cancer and diabetes, to neurodegenerative, inflammatory, gastrointestinal, cardiovascular, and behavioral disorders. GPCRs are therefore of utmost interest in homeostatic regulation, pathophysiologic states, and drug development.
Repeated or sustained application of agonists rapidly decreases signaling by the corresponding GPCR in response to subsequent challenge with the same ligand, a process known as homologous desensitization. A widely accepted model envisages that inactivation of GPCR signaling in the setting of homologous desensitization is initiated by G protein-coupled receptor kinase (GRK) which phosphorylates the COOH-terminal tail and/or third intracellular loop of activated GPCRs (12) , thereby promoting the recruitment of ␤-arrestins and formation of a molecular complex between the activated (ligand-bound) and phosphorylated GPCR and arrestin (Fig. 1) . The binding of ␤-arrestin to the activated GPCR uncouples the receptor from the ␣-subunit of heterotrimeric G proteins, thereby causing desensitization. ␤-Arrestin also recruits cellular proteins (e.g., clathrin) that mediate GPCR internalization, traffic, and intracellular sorting (6, 8) , leading to recycling of a resensitized (dephosphorylated) GPCR or, alternatively, to GPCR degradation (Fig. 1) .
In recent years, it has become apparent that GPCRs also mediate intracellular signaling through G protein-independent pathways, e.g., via ␤-arrestin (13) , and that the mechanisms leading to GPCR desensitization, trafficking, and resensitization are far more complex than initially thought. There are multiple GRK isoforms (GRK 1-7) that bind the active conformation of GPCRs in different cell types (5) . In turn, different GRKs phosphorylate different residues in the receptor, leading to different outcomes. GRKs act not only through phosphorylation-dependent (14) but also via phosphorylationindependent (4) mechanisms, including sequestration of heterotrimeric G proteins (19) . GPCRs can also be phosphorylated by other protein kinases, including protein kinase A (PKA) and members of the PKC family, in a cell context-dependent manner. There are at least two nonvisual arrestins (␤-arrestin 1 and ␤-arrestin 2, also termed arrestin 2 and arrestin 3, respectively) which can recruit different proteins and thereby not only initiate GPCR desensitization and internalization but also promote signaling by the internalized receptor (21) . Thus, GPCR function is regulated at multiple levels by a large number of interacting proteins, including kinases, phosphatases, and scaffolds that assemble molecular complexes and fine tune the transduction of the GPCR signal initiated at the cell surface by the binding of an agonistic ligand.
Tachykinins are a family of biologically active peptides distributed in the central and peripheral nervous system. Three distinct GPCR subtypes have been identified for tachykinins, designated as neurokinin 1 receptor (NK 1 R), NK 2 R, and NK 3 R. The most potent of the tachykinins, the undecapeptide substance P (SP), binds preferentially to NK 1 R. Many reports have demonstrated that repeated application of SP induces acute homologous desensitization of NK 1 R signaling followed by resensitization (1, 9, 15, 20) . In line with other GPCR/ligand systems, this process has been envisaged to proceed through three steps: 1) internalization of the ligand-bound, ␤-arrestincomplexed, and phosphorylated NK 1 R; 2) release of ligand, dissociation of the NK 1 R/␤-arrestin complex, and NK 1 R dephosphorylation in endosomes; and 3) recycling of the receptor to the cell surface. The study by Murphy, Roosterman, and colleagues in this issue of American Journal of PhysiologyCell Physiology (9) addresses the contribution of internalization and recycling to the resensitization of NK 1 R function. A comparison of the time courses of recovery of SP binding sites at the cell surface and SP-induced Ca 2ϩ mobilization led the authors to the surprising conclusion that reactivation of NK 1 R located at the plasma membrane is the primary mechanism of resensitization of SP-induced Ca 2ϩ signaling. To study the mechanisms involved, Murphy, Roosterman, and colleagues (9) utilize several approaches to demonstrate that SP induces interaction of serine/threonine-protein phosphatase 2A (PP2A) and ␤-arrestin1 at the plasma membrane and that ␤-arrestin1, PP2A, and NK 1 R form a molecular complex, as shown by immunoprecipitation of surface-local-ized NK 1 R. Previously, the authors demonstrated that the metalloendopeptidase endothelin-converting enzyme 1 (ECE-1) determines stability of the SP/NK 1 R/␤-arrestin1 complex and regulates receptor recycling and resensitization (15) . In the current report, they observe that an inhibitor of ECE-1 markedly reduced the interaction of surface-localized NK 1 R with ␤-arrestin1 and PP2A. They suggest that SP-induced formation of the NK 1 R/␤-arrestin1/PP2A complex at the plasma membrane is promoted by ECE-1, possibly by liberating ␤-arrestin1 sequestered in endosomes by internalized NK 1 R (9). A test of this interpretation must await further information concerning the stoichiometry of the molecular players. To test whether PP2A plays a role in mediating reactivation of NK 1 R localized at the plasma membrane, two different PP2A inhibitors, okadaic acid and fostriecin, were used. Treatment with these inhibitors partially inhibited resensitization of Ca 2ϩ signaling via NK 1 R. Interestingly, an inhibitor of PKC activity attenuated the recovery of NK 1 R function, implying that PKC activity might be required to achieve NK 1 R resensitization. Murphy, Roosterman, and colleagues (9) conclude that these findings provide evidence for a novel mechanism of GPCR resensitization. Specifically, the phosphorylated and desensitized noninternalized receptor regains activity, at least in part via PP2A-mediated dephosphorylation. Another interesting aspect of their conclusions is that ␤-arrestin1 not only mediates homologous desensitization but also appears to be required for promoting resensitization by bringing PP2A to the plasma membrane. A previous study by Bennett et al. (1) using Chinese hamster ovary cells stably expressing the NK 1 R also concluded that resensitization of responsiveness to substance P precedes receptor recycling and proposed that resensitization may result from a conversion of nonfunctional neurokinin 1 receptors to functional receptors at the plasma membrane.
As recognized by the authors, their interpretations have a number of limitations. Studies with NK 1 R internalizationdeficient mutants would have been highly desirable to obtain direct evidence that desensitization/resensitization occurs at the plasma membrane. Furthermore, the phosphorylation/dephosphorylation cycles that are posited to play a key role in the desensitization/resensitization process have not been validated by any direct assessment of receptor phosphorylation. The development of antibodies that detect the phosphorylated state of specific NK 1 R residues, as has been done with other GPCRs (2, 3), would be an important advance in this area. In this context, the possibility that PKC plays a role in resensitization was based on the observation that the PKC inhibitor GF 109203X blunted the recovery of NK 1 R responsiveness to SP. The authors suggest that PKC-mediated phosphorylation of NK 1 R creates binding sites for the ␤-arrestin1/PP2A complex, thereby bringing PP2A in close proximity to NK 1 R to catalyze its dephosphorylation. Additional work with other PKC inhibitors and RNA silencing of different PKC isoforms will be necessary for clarifying this point. In addition, PKC could act indirectly, e.g., through activation of downstream targets, including the kinases of the PKD family (17) . It is also noteworthy that cell treatment with the protein phosphatase inhibitors okadaic acid and fostriecin had only a modest effect in preventing NK 1 R resensitization. As the authors recognize, these results might indicate the operation of other, PP2A-independent pathways of NK 1 R recovery of responsiveness to SP.
Extensive studies on GPCR signaling have revealed previously unsuspected connections and complexities of these signal transducers. These include the realization that GPCRs can form homo-and/or heterodimers and interact with several rather than a single G protein, that heterotrimeric G proteins regulate small monomeric G proteins and that GPCRs can also signal through G protein-independent mechanisms (13, 21) . It is conceivable that GPCRs function as subunits of large multiprotein signaling complexes that assemble and disassemble in special microdomains (e.g., lipid rafts) of the plasma membrane (10, 18) . The results of Murphy, Roosterman, and colleagues in this issue raise the novel possibility that a subpopulation of NK 1 Rs appears to Fig. 1 . Sequence of events in neurokinin 1 receptor (NK1R) desensitization/resensitization. Ligand (L) binding to its cognate G protein-coupled receptor (GPCR) causes a conformational change leading to activation of heterotrimeric G proteins coupled to the GPCR, promoting their dissociation into G␣ and G␤␥ and the exchange of GDP bound to G␣ for GTP. The resulting GTP-G␣ complex activates downstream effectors (e.g., phospholipase C, adenylyl cyclase, not shown in the scheme). Ligand-activated GPCR increases its affinity for GPCR kinases (GRKs) which mediate GPCR phosphorylation and generate sites for ␤-arrestin (␤-Arr) recruitment. The binding of ␤-arrestin induces homologous desensitization (i.e., uncoupling of the GPCR from interacting G proteins) and activation of non-G protein-dependent signaling. ␤-Arrestin also promotes the recruitment of proteins that mediate GPCR internalization, dephosphorylation [e.g., protein phosphatase 2A (PP2A)], resensitization, and recycling back to the membrane (blue arrows). The results of Murphy, Roosterman, and colleagues raise the possibility that resensitization of NK1R via ␤-arrestin/PP2A-mediated dephosphorylation occurs, at least in part, at the plasma membrane (red arrow).
